share_log

Reported Earlier, Adaptimmune's TECELRA Gains U.S. FDA Accelerated Approval As First Engineered Cell Therapy For Solid Tumors

Reported Earlier, Adaptimmune's TECELRA Gains U.S. FDA Accelerated Approval As First Engineered Cell Therapy For Solid Tumors

适应免疫技术的TECELRA作为首个用于实体瘤工程细胞疗法获得美国FDA的加速批准
Benzinga ·  08/02 03:17
  • Approved for advanced MAGE-A4+synovial sarcoma in adults with certain HLA types who have received prior chemotherapy
  • TECELRA is the first new treatment option for people with synovial sarcoma in more than a decade
  • 爱文思控股公司的高级MAGE-A4+滑膜肉瘤治疗药物获批,适用于成年人中特定HLA类型的人群,在接受过化疗治疗后。
  • TECELRA是十年来滑膜肉瘤患者的第一个新治疗选择。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发